European Medicines Agency recommends granting a marketing authorisation for dabrafenib

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product dabrafenib (Tafinlar), 50 and 75 mg capsules, hard, intended for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Read more here.